Is the US prepared to deal with another pandemic or widespread health crisis?
Short answer: better than in 2019, but still not where we need to be.
Where the U.S. is stronger now
•Earlier detection. CDC’s wastewater network now tracks multiple pathogens (COVID‑19, influenza A/H5, RSV, measles, mpox) nationwide, and airport-based traveler genomics has scaled past 1 million participants—both provide earlier warning of new threats. CDC’s forecasting center also issues seasonal respiratory outlooks used by health systems.[1]
•More organized medical countermeasure planning. HHS has reconstituted its interagency PHEMCE process, publishes a Strategy & Implementation Plan, and runs annual threat-based reviews to steer the Strategic National Stockpile (SNS) and R&D investments. Supply‑chain/industrial‑base work is more deliberate than before COVID‑19.[2]
•Stockpile coordination has improved. GAO reports HHS has implemented key fixes, including formal guidance clarifying roles and an online portal for jurisdictions to request SNS assets—problems that hampered COVID and mpox responses.[3]
•Border surveillance. CDC’s Traveler‑Based Genomic Surveillance continues at major U.S. airports and has demonstrated value by flagging variants earlier than routine systems.[4]
Where significant gaps remain
•Core public‑health and hospital surge capacity. Federal preparedness grants have not kept pace with needs. The Hospital Preparedness Program (HPP) budget remains far below its post‑9/11 peak (about $240M in FY 2026 per AHA), and GAO and TFAH note persistent variation and underfunding across states.[5]
•Workforce. Surveys and GAO analyses show state and local health agencies still face large staffing shortfalls and retention issues—conditions that complicate surge hiring during emergencies.[6]
•Unfinished policy framework. Congress has relied on short extensions rather than a full reauthorization of the Pandemic and All‑Hazards Preparedness Act (PAHPA); several authorities were only extended through January 30, 2026, and health groups are still urging comprehensive renewal as of September 2026. That creates uncertainty for programs like HPP and data/supply‑chain efforts.[7]
•Mixed signals on countermeasure R&D/manufacturing. While HHS continues some platform and industrial‑base work, it also announced a wind‑down of BARDA’s mRNA vaccine development activities in 2025—introducing uncertainty about rapid vaccine scale‑up for future threats.[8]
•International coordination. WHO’s 2024 amendments to the International Health Regulations are moving toward entry into force globally, but the U.S. government transmitted a rejection of those amendments in 2025. That stance may complicate future cross‑border data sharing and standards alignment during fast‑moving events.[9]
•GAO still lists HHS leadership/coordination for public‑health emergencies on its High‑Risk List (most recently updated for the 2025 cycle), citing many open recommendations around surveillance, stockpile management, and interagency coordination.[10]
Bottom line
•Compared with 2020, the U.S. has meaningfully better early‑warning systems, clearer stockpile playbooks, and a more intentional (though still evolving) medical‑supply industrial base. But chronic underinvestment in state/local health departments and hospital surge capacity, unresolved workforce shortages, and an unsettled federal policy framework (PAHPA and international rules) leave real vulnerabilities. A high‑impact, fast‑moving outbreak could still outstrip parts of the system before countermeasures and logistics fully mobilize.[11]
What would move the needle most
•Fully reauthorize and multi‑year fund PAHPA (including HPP and CDC’s PHEP) to end the “boom‑bust” cycle.[7]
•Stabilize the workforce (pay/benefits, hiring speed, training pipelines) using PH WINS data to target roles with the highest attrition.[12]
•Lock in rapid‑vaccine and diagnostic capacity across platforms (including mRNA) with clear surge manufacturing contracts and domestic API/device supply‑chain incentives.[8]
•Finish data modernization and interoperability so jurisdictions can share situational awareness in near real time without ad‑hoc workarounds.[13]
•Maintain and regularly exercise SNS distribution with states, tribes, and health systems under the updated guidance.[3]
If you want, tell me your state, and I can summarize its current preparedness grants and capabilities (e.g., wastewater coverage, recent PHEP funding) to make this more concrete.[14]
Backs: “GAO reports HHS has implemented key fixes, including formal guidance clarifying roles and an online portal for jurisdictions to request SNS assets—problems that hampered COVID and mpox responses.”
Backs: “CDC’s Traveler‑Based Genomic Surveillance continues at major U.S. airports and has demonstrated value by flagging variants earlier than routine systems.”
Backs: “The Hospital Preparedness Program (HPP) budget remains far below its post‑9/11 peak (about $240M in FY 2026 per AHA), and GAO and TFAH note persistent variation and underfunding across states.”
Backs: “Surveys and GAO analyses show state and local health agencies still face large staffing shortfalls and retention issues—conditions that complicate surge hiring during emergencies.”
Backs: “While HHS continues some platform and industrial‑base work, it also announced a wind‑down of BARDA’s mRNA vaccine development activities in 2025—introducing uncertainty about rapid vaccine scale‑up for future threats.”
Backs: “GAO still lists HHS leadership/coordination for public‑health emergencies on its High‑Risk List (most recently updated for the 2025 cycle), citing many open recommendations around surveillance, stockpile management, and interagency coordination.”
Backs: “If you want, tell me your state, and I can summarize its current preparedness grants and capabilities (e.g., wastewater coverage, recent PHEP funding) to make this more concrete.”